Compare ARTNA & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ARTNA | LRMR |
|---|---|---|
| Founded | 1905 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Water Supply | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 346.0M | 332.1M |
| IPO Year | 1996 | N/A |
| Metric | ARTNA | LRMR |
|---|---|---|
| Price | $31.92 | $3.94 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $16.71 |
| AVG Volume (30 Days) | 24.6K | ★ 1.4M |
| Earning Date | 10-30-2025 | 11-05-2025 |
| Dividend Yield | ★ 3.92% | N/A |
| EPS Growth | ★ 12.02 | N/A |
| EPS | ★ 2.18 | N/A |
| Revenue | ★ $111,776,000.00 | N/A |
| Revenue This Year | $7.82 | N/A |
| Revenue Next Year | $3.54 | N/A |
| P/E Ratio | $14.66 | ★ N/A |
| Revenue Growth | ★ 5.80 | N/A |
| 52 Week Low | $29.45 | $1.61 |
| 52 Week High | $36.19 | $6.48 |
| Indicator | ARTNA | LRMR |
|---|---|---|
| Relative Strength Index (RSI) | 56.10 | 55.08 |
| Support Level | $30.89 | $3.12 |
| Resistance Level | $31.70 | $4.09 |
| Average True Range (ATR) | 0.60 | 0.25 |
| MACD | 0.15 | 0.07 |
| Stochastic Oscillator | 88.95 | 79.13 |
Artesian Resources Corp operates as a holding company with a focus on water distribution and wastewater services. Its regulated utility segment includes subsidiaries providing water and wastewater services in Delaware, Maryland, and Pennsylvania. Water distribution spans residential, commercial, industrial, and municipal sectors, while wastewater services are offered in Sussex County, Delaware. The company also engages in non-utility businesses, offering service line protection plans, engineering services, and contract operations for water and wastewater systems. The regulated utility segment constitutes the portion of the company's operations, subject to regulations by Delaware, Maryland, and Pennsylvania.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.